17 employees
AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline.
2022
$30M
from 7 investors over 7 rounds
AstriVax raised $30M on August 25, 2022
Investors: KU Leuven Innovation & Entrepreneurship, V-Bio Ventures, Merieux Equity Partners, Ackermans & van Haaren, Thuja Capital, BNP Paribas Fortis and FundPlus